Hainan Huluwa Pharmaceutical Group Co., Ltd.

Shanghai Stock Exchange 605199.SS

Hainan Huluwa Pharmaceutical Group Co., Ltd. Total Non-Current Liabilities for the year ending December 31, 2023: USD 115.31 M

Hainan Huluwa Pharmaceutical Group Co., Ltd. Total Non-Current Liabilities is USD 115.31 M for the year ending December 31, 2023, a 231.69% change year over year. Total non-current liabilities are the sum of long-term debt and other non-current liabilities.

Hainan Huluwa Pharmaceutical Group Co., Ltd. Total Non-Current Liabilities for the year ending December 31, 2022 was USD 34.76 M, a 505.85% change year over year.
Hainan Huluwa Pharmaceutical Group Co., Ltd. Total Non-Current Liabilities for the year ending December 31, 2021 was USD 5.74 M, a -37.74% change year over year.
Hainan Huluwa Pharmaceutical Group Co., Ltd. Total Non-Current Liabilities for the year ending December 31, 2020 was USD 9.22 M, a 46.46% change year over year.
Hainan Huluwa Pharmaceutical Group Co., Ltd. Total Non-Current Liabilities for the year ending December 31, 2019 was USD 6.29 M, a -52.26% change year over year.

Key data

Date	Total Non-Current Liabilities	Shareholders' Equity	Other Liabilities	Total Liabilities

Shanghai Stock Exchange: 605199.SS

Hainan Huluwa Pharmaceutical Group Co., Ltd.

CEO	Ms. Jinping Liu
IPO Date	July 10, 2020
Location	China
Headquarters	No. 8, Yaogu 4th Road
Employees	2,468
Sector	Consumers Staples
Industries Baby & Childcare Pharmaceuticals Vaccines

Description

Hainan Huluwa Pharmaceutical Group Co., Ltd. engages in the research and development, production, and sale of drugs in the areas of Children's respiratory and digestive systems in China. Its primary products include 4 grams of pediatric lung heat cough granules and capsules. The company was founded in 2005 and is based in Haikou, China.

Key trends

Past 5 years